Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea.
Gynecol Obstet Invest. 2011;71(1):11-8. doi: 10.1159/000320719. Epub 2010 Dec 15.
To identify a molecular marker associated with volumetric changes to radiotherapy (RT) in cervical cancer, we compared gene expression profiles of an early response (ER) group with a late response (LR) group, which are defined by complete and partial disappearance of a primary cervical lesion on MRI performed 1 month after completion of RT.
Microarray analysis of mRNA expression profiles was performed in 17 patients (11 in the ER and 6 in the LR group). After selection of the genes with significant differential expression, we evaluated the association of the selected genes with radioresistance in clinical specimens.
We identified 53 genes with differential expression on microarray analysis using the permutation test with t statistics (p ≤ 0.01). Using immunohistochemistry, we evaluated the expression of RAR-β, one of the genes selected among the differentially expressed genes. RAR-β expression was significantly down-regulated in the LR group compared with the ER group (p = 0.02). However, this gene did not predict permanent radioresistance (p = 0.19).
RAR-β expression might be a valuable marker for the prediction of early volumetric changes to RT in cervical carcinomas. Further search for additional genes associated with early volumetric changes and radioresistance may aid in refining individual treatment strategies.
为了确定与宫颈癌放射治疗（RT）体积变化相关的分子标志物，我们比较了磁共振成像（MRI）检查在 RT 完成后 1 个月显示原发性宫颈病变完全或部分消失的早期反应（ER）组和晚期反应（LR）组的基因表达谱。
对 17 例患者（ER 组 11 例，LR 组 6 例）进行了 mRNA 表达谱的微阵列分析。在选择具有显著差异表达的基因后，我们评估了所选基因与临床标本中放射性抗性的相关性。
我们使用置换检验 t 统计量（p≤0.01）对微阵列分析中差异表达的基因进行了 53 个基因的识别。使用免疫组织化学，我们评估了所选差异表达基因之一 RAR-β 的表达。与 ER 组相比，LR 组 RAR-β 的表达明显下调（p=0.02）。然而，该基因并不能预测永久性放射性抗性（p=0.19）。
RAR-β 的表达可能是预测宫颈癌 RT 早期体积变化的有价值的标志物。进一步寻找与早期体积变化和放射性抗性相关的其他基因可能有助于完善个体化治疗策略。
